Latest Bcl-2 Stories
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.
Scientists at Trinity College Dublin have made an important discovery concerning how fledgling cancer cells self-destruct, which has the potential of impacting on future cancer therapies.
New research led by UC Davis scientists provides insight into why some body organs are more susceptible to cell death than others and could eventually lead to advances in treating or preventing heart attack or stroke.
Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.
Adding a second agent may make a new, experimental anti-cancer drug effective against a wide range of cancers, researchers at the University of Illinois at Chicago College of Medicine have found.
Cholangiocarcinoma (CCA) is a malignant tumor, characterized by a poor prognosis and unresponsive to conventional chemotherapeutic agents.
The TRAIL ligand is a promising anticancer agent that preferentially kills tumor cells without apparent damage to healthy cells.
Researchers find out why estrogen-positive tumors stop responding to commonly used drugs, pointing a way to new therapies.
Walter and Eliza Hall Institute scientists have identified a key step in the biological process of programmed cell death, also called apoptosis.
Two different anti-apoptotic proteins support cancer cell survival via an identical mechanism, yet differ in their sensitivity to chemotherapeutic drugs, report Brunelle et al.
- totally perplexed and mixed up.